The potential of RNA therapeutics is currently being explored in relation to signalling that leads to HF, for example due to genetic predisposition (e.g. amyloidosis, muscular dystrophy or the pathogenic variant PLN R14del). The gene discussed is PLN; the disease is hydrops fetalis.